Nonalcoholic Fatty Liver Disease (NAFLD) affects 24% of the US population and only 5% are aware of their disease. That’s staggering when you consider how NAFLD can progress to Nonalcoholic Steato Hepatitis, Cirrhosis, and Hepatoma.
How can we diagnose and follow these patients in a primary care setting? What treatments are available? What is the data on these treatments?
Please join Peter Buch, MD as he discusses the important role that you will play in treating a tsunami of future liver disease due to NAFLD. This will be done in a practical, case based, very interactive and fun format. You’ll conclude with practical, useful clinical tools necessary to help you NAFLD patients.
Planning Committee Disclosure - No relevant relationships
All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners. For speaker disclosures, please see the faculty biography.
NOTE: Tuition includes one free CE Certificate (participant will be able to print the certificate of completion after passing the online post-test (80% passing score) and completing the evaluation). Instructional methods will include PowerPoint, didactic lecture, and others.
Continuing Education Information: Listed below are the continuing education credit(s) currently available for this non-interactive self-study package. Program content is reviewed periodically per accrediting board rules for currency and appropriateness for credit. Credit approvals are subject to change. Please note, your state licensing board dictates whether self-study is an acceptable form of continuing education, as well as which credit types are acceptable for continuing education hours. Please refer to your state rules and regulations. If your profession is not listed, please contact your licensing board to determine your continuing education requirements and check for reciprocal approval.
For other credit inquiries not specified below, please contact info@pesi.com or 800-844-8260 before purchase.
Materials that are included in this course may include interventions and modalities that are beyond the authorized practice of your profession. As a licensed professional, you are responsible for reviewing the scope of practice, including activities that are defined in law as beyond the boundaries of practice in accordance with and in compliance with your profession's standards.
For Planning Committee disclosures, please see the statement above. For speaker disclosures, please see the faculty biography.
Earn up to 2.0 CE hours. Please see below, for more details, as credit amounts vary by state and profession.
This self-study program offers 127 instructional minutes of pharmacology content which is designed to qualify for 2.0 contact hours toward your pharmacology requirement.
PESI, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses completing these self-study materials will earn 2.0 contact hours. Expires: 12/08/2026.
PESI, Inc. is a provider approved by the California Board of Registered Nursing, Provider #: 17118 for 2.0 self-study contact hours.
** You will need to provide your license number to PESI. PESI must have this number on file in order for your hours to be valid.
PESI, Inc. is an approved provider by the Florida Board of Nursing. Provider #: FBN2858. These materials qualify for 2.0 self-study contact hours.
PESI, Inc. is an approved provider by the Iowa Board of Nursing. Provider #: 346. Nurses successfully completing these self-study materials will earn 2.0 self-study contact hours. Please email cepesi@pesi.com with your license number, include the title, speaker name and date. PESI must have this number on file in order for your hours to be valid.
PESI, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. PESI, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. This activity was originally recorded on 12/08/2023. It was last reviewed on 03/15/2024 and is valid until 03/14/2027.
Physicians should only claim credit commensurate with the extent of their participation in the activity. You are required to successfully complete and submit a post-test prior to receiving a certificate of completion.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME such as PESI. Physician assistants may receive a maximum of 2.0 hours for completing this self-study program. This activity was originally recorded on 12/08/2023. It was last reviewed on 03/15/2024 and is valid until 03/14/2027.
PESI, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. PESI, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™.
This self-study activity qualifies for 2.0 continuing education clock hours as required by many national, state and local licensing boards and professional organizations. Save your activity advertisement and certificate of completion, and contact your own board or organization for specific requirements.
File type | File name | Number of pages | |
---|---|---|---|
Manual - The Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease, Nonalcoholic Steato Hepatitis, Cirrhosis, &Hepatoma (8 MB) | 75 Pages | Available after Purchase |
Peter Buch, MD, AGAF, FACP, is a double board-certified clinical gastroenterologist, leading a team that treats all GI conditions. Dr. Buch sits on editorial boards for numerous professional journals and is a highly sought-after international presenter.
Dr. Buch has a passion for teaching. His style is case-based, practical, very interactive and evidence supported. Dr. Buch’s expertise has been shared with experienced clinicians and advanced-level students. He teaches at the University of Connecticut School of Medicine, the University of New England College of Osteopathic Medicine, the Frank H Netter School of Medicine/Quinnipiac University and the University of Connecticut APRN School.
Speaker Disclosures:
Financial: Dr. Peter S. Buch has employment relationships with the University of Connecticut School of Medicine, the University of New England College of Osteopathic Medicine, and the Frank H Netter, MD School of Medicine. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Peter S. Buch serves on the FDA and Patient Care Committees at the American College of Gastroenterology. He serves as an editor of peer-reviewed journals. He is a member of the International Association of Medical Science Educators, the AGA Academy of Educators, the American Gastroenterological Association (AGAF), the American College of Physicians (FACP), the Hartford County Medical Association, the American College of Gastroenterology (FACG), and the Connecticut State Medical Society.
Content Disclosure:
Dr. Buch references the use of antidepressants for Irritable Bowel Syndrome, and the controversial use of Fibrotest to evaluate patients with fatty liver disease who may have fibrosis of the liver. Dr. Buch indicates he wishes to present a fair and balanced approach to practitioners regarding such practices.
Access never expires for this product.
Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info
Changing Terminology
Evaluation of a Patient with Mildly Elevated Liver Function Tests
Necessary Testing
Risk Factors for Nonalcoholic Fatty Liver Disease (NAFLD)
NAFLD Diagnosis
Techniques to Determine Alcohol Consumption
Usefulness of Labs to Determine Alcohol Consumption
Importance of Nonalcoholic Steatohepatitis (NASH) in Primary Care
Progression of NAFLD
Non-Invasive Tests to Check for Progression of Liver Disease
Imaging in Nonalcoholic Fatty Liver Disease
When is a Liver Biopsy Still Needed to Make the Diagnosis
Why Patients with NAFLD have a 10% Higher Mortality Rate
Standard Ways of Treating NAFLD
How do we approach NAFLD in lean individuals?
Medications used to treat NASH
Bariatric Surgery for NASH
Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to: PO Box 1000, Eau Claire, WI 54702-1000 or call 1-800-844-8260.
ADA Needs
We would be happy to accommodate your ADA needs; please call our Customer Service Department for more information at 1-800-844-8260.
PESI Mobile App
Access CE trainings on your phone or tablet through our free mobile app. Choose video or audio-only versions of online courses from the world’s best instructors, and complete your CE requirements anywhere, anytime, at your own pace.
Please wait ...